Brief: Irlab Granted Additional Patent For Its Drug Candidate Pirepemat

IRLAB Therapeutics AB

18/09/2024 06:06

Sept 18 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB GRANTED ADDITIONAL PATENT FOR ITS DRUG CANDIDATE
PIREPEMAT
EXPANDING THE PATENT PROTECTION IN THE US
    * LATEST PATENT, COVERING SALT OF DRUG USED IN ONGOING
CLINICAL
DEVELOPMENT, HAS PREVIOUSLY BEEN GRANTED IN EUROPE, JAPAN AND
CHINA, PREDICTED TO EXPIRE IN 2038
    * WITH AWARDED PATENT TERM ADJUSTMENT (PTA) AND POTENTIAL
GRANT OF
PATENT TERM EXTENSION (PTE), EXCLUSIVITY IN US WILL REACH INTO
EARLY 2040S

Source text for Eikon:  ID:nMFN60vsCQ 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))